Effect of integrin targeting and PEG shielding on polyplex micelle internalization studied by live-cell imaging

alpha(v)beta(3) and alpha(v)beta(5) integrins are attractive target structures for cancer therapy as they are upregulated in tumor and tumor associated host cells and play a pivotal role for tumor growth and metastasis. Gene vectors such as polyplex micelles consisting of thiolated PEG-block-poly(lysine) copolymers complexed with plasmid DNA can be targeted to these specific integrins by equipment with a cyclic RGD peptide. In this study, we analyzed the effect of the RGD ligand on micelle endocytosis by comparing fluorescently labeled, targeted and untargeted micelles in live-cell imaging experiments with highly sensitive fluorescence microscopy and flow cytometry. Two micelle types with 12 kDa (PEG12) and 17 kDa (PEG17) PEG shell layers were examined to evaluate the influence of surface shielding on the internalization characteristics. Our results reveal three major effects: First, the RGD ligand accelerates the internalization of micelles into integrin expressing HeLa cells without changing the uptake pathway of the micelles. Both targeted as well as untargeted micelles are predominantly internalized via clathrin mediated endocytosis. Second, the PEG shielding of micelles has an important effect on their targeting specificity. At high PEG shielding selective endocytosis of integrin targeted micelles occurs, whereas at low PEG shielding targeted and untargeted micelles show comparable internalization. In addition, PEG17 RGD(+) micelles induce the highest reporter gene expression. Third, our data demonstrate a clear influence of the applied micelle dose on the internalization of integrin targeted micelles. We propose that PEG17 shielded micelles equipped with a cyclic RGD ligand are the favored system of choice for clinical therapy as they exhibit higher transgene expression, a higher specificity for integrin-dependent endocytosis compared to PEG12 shielded micelles, and are functional at low doses as well. (C) 2011 Elsevier B.V. All rights reserved.